Relation of epidermal growth factor receptor, phosphorylated-Akt, and hypoxia-inducible factor-1alpha in non-small cell lung cancers.

[1]  B. Vonderhaar.  Hormonal interactions during mammary gland development , 2003, Breast Cancer Research.

[2]  David Cella,et al.  Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. , 2003, JAMA.

[3]  T. Mukohara,et al.  Expression of epidermal growth factor receptor (EGFR) and downstream-activated peptides in surgically excised non-small-cell lung cancer (NSCLC). , 2003, Lung cancer.

[4]  Masahiro Fukuoka,et al.  Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Sone,et al.  Phosphorylation, but not overexpression, of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients. , 2003, Oncology research.

[6]  C. Harris,et al.  Rapid Akt activation by nicotine and a tobacco carcinogen modulates the phenotype of normal human airway epithelial cells. , 2003, The Journal of clinical investigation.

[7]  Olle Stål,et al.  Akt kinases in breast cancer and the results of adjuvant therapy , 2003, Breast Cancer Research.

[8]  P. Sutphin,et al.  Role of Prolyl Hydroxylation in Oncogenically Stabilized Hypoxia-inducible Factor-1α* , 2002, The Journal of Biological Chemistry.

[9]  G. Semenza.  Signal transduction to hypoxia-inducible factor 1. , 2002, Biochemical pharmacology.

[10]  Won Sang Park,et al.  Non‐small cell lung cancers frequently express phosphorylated Akt; an immunohistochemical study , 2002, APMIS : acta pathologica, microbiologica, et immunologica Scandinavica.

[11]  C. Thompson,et al.  Phosphatidylinositol 3-Kinase/Akt Signaling Is Neither Required for Hypoxic Stabilization of HIF-1α nor Sufficient for HIF-1-dependent Target Gene Transcription* , 2002, The Journal of Biological Chemistry.

[12]  M. Álvarez-Tejado,et al.  Lack of Evidence for the Involvement of the Phosphoinositide 3-Kinase/Akt Pathway in the Activation of Hypoxia-inducible Factors by Low Oxygen Tension* , 2002, The Journal of Biological Chemistry.

[13]  R. Weber,et al.  Local recurrence in head and neck cancer: relationship to radiation resistance and signal transduction. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[14]  A. Harris,et al.  Expression of hypoxia-inducible carbonic anhydrase-9 relates to angiogenic pathways and independently to poor outcome in non-small cell lung cancer. , 2001, Cancer research.

[15]  A. Harris,et al.  Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival , 2001, British Journal of Cancer.

[16]  P. Dennis,et al.  Akt/protein kinase B is constitutively active in non-small cell lung cancer cells and promotes cellular survival and resistance to chemotherapy and radiation. , 2001, Cancer research.

[17]  A. Harris,et al.  Hypoxia inducible factor (HIF-1a and HIF-2a) expression in early esophageal cancer and response to photodynamic therapy and radiotherapy. , 2001, Cancer research.

[18]  Y. Yamashita,et al.  K-ras gene mutations in non-small cell lung cancer in Japanese. , 2000, Oncology reports.

[19]  C. Conover,et al.  Insulin-like growth factor (IGF) binding protein-3 potentiation of IGF action is mediated through the phosphatidylinositol-3-kinase pathway and is associated with alteration in protein kinase B/AKT sensitivity. , 2000, Endocrinology.

[20]  M. Schindl,et al.  Overexpression of hypoxia-inducible factor 1alpha is a marker for an unfavorable prognosis in early-stage invasive cervical cancer. , 2000, Cancer research.

[21]  M. Volm,et al.  Hypoxia-inducible factor (HIF-1) and its relationship to apoptosis and proliferation in lung cancer. , 2000, Anticancer research.

[22]  G. Semenza,et al.  Modulation of hypoxia-inducible factor 1alpha expression by the epidermal growth factor/phosphatidylinositol 3-kinase/PTEN/AKT/FRAP pathway in human prostate cancer cells: implications for tumor angiogenesis and therapeutics. , 2000, Cancer research.

[23]  A. Koong,et al.  Loss of PTEN facilitates HIF-1-mediated gene expression. , 2000, Genes & development.

[24]  S. R. Datta,et al.  Cellular survival: a play in three Akts. , 1999, Genes & development.

[25]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[26]  J. Muscat,et al.  K-ras oncogene mutation as a prognostic marker in non-small cell lung cancer: a combined analysis of 881 cases. , 1999, Carcinogenesis.

[27]  C. Wykoff,et al.  The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis , 1999, Nature.

[28]  M. Greenberg,et al.  Akt Promotes Cell Survival by Phosphorylating and Inhibiting a Forkhead Transcription Factor , 1999, Cell.

[29]  John Calvin Reed,et al.  Regulation of cell death protease caspase-9 by phosphorylation. , 1998, Science.

[30]  S. R. Datta,et al.  Akt Phosphorylation of BAD Couples Survival Signals to the Cell-Intrinsic Death Machinery , 1997, Cell.

[31]  M. Oda,et al.  Relationship between microlymphatic vessel density within tumors and lymph node metastasis. , 1997, Oncology reports.

[32]  E. Dmitrovsky,et al.  Overexpression of the epidermal growth factor receptor and its ligand transforming growth factor alpha is frequent in resectable non-small cell lung cancer but does not predict tumor progression. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.